Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.

Gantenbein, Andreas R; Agosti, Reto; Kamm, Christian P; Landmann, Gunther; Meier, Niklaus; Merki-Feld, Gabriele Susanne; Petersen, Jens A; Pohl, Heiko; Ryvlin, Philippe; Schankin, Christoph J; Viceic, Dragana; Zecca, Chiara; Schäfer, Elisabeth; Meyer, Ina; Arzt, Michael E (2022). Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results. The journal of headache and pain, 23(1), p. 142. 10.1186/s10194-022-01515-8

s10194-022-01515-8.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview


The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine. To complement findings from the pivotal program, this observational study was designed to collect and evaluate clinical data on the impact of erenumab on several endpoints, such as quality of life, migraine-related impairment and treatment satisfaction in a real-world setting.


An interim analysis was conducted after all patients completed 6 months of erenumab treatment. Patients kept a headache diary and completed questionnaires at follow up visits. The overall study duration comprises 24 months.


In total, 172 adults with chronic or episodic migraine from 19 different sites across Switzerland were enrolled to receive erenumab every 4 weeks. At baseline, patients had 16.6 ± 7.2 monthly migraine days (MMD) and 11.6 ± 7.0 acute migraine-specific medication days per month. After 6 months, erenumab treatment reduced Headache Impact Test (HIT-6™) scores by 7.7 ± 8.4 (p < 0.001), the modified Migraine Disability Assessment (mMIDAS) by 14.1 ± 17.8 (p < 0.001), MMD by 7.6 ± 7.0 (p < 0.001) and acute migraine-specific medication days per month by 6.6 ± 5.4 (p < 0.001). Erenumab also reduced the impact of migraine on social and family life, as evidenced by a reduction of Impact of Migraine on Partners and Adolescent Children (IMPAC) scores by 6.1 ± 6.7 (p < 0.001). Patients reported a mean effectiveness of 67.1, convenience of 82.4 and global satisfaction of 72.4 in the Treatment Satisfaction Questionnaire for Medication (TSQM-9). In total, 99 adverse events (AE) and 12 serious adverse events (SAE) were observed in 62 and 11 patients, respectively. All SAE were regarded as not related to the study medication.


Overall quality of life improved and treatment satisfaction was rated high with erenumab treatment in real-world clinical practice. In addition, the reported impact of migraine on spouses and children of patients was reduced.


BASEC ID 2018-02,375 in the Register of All Projects in Switzerland (RAPS).

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Kamm, Christian Philipp, Schankin, Christoph Josef


600 Technology > 610 Medicine & health






Pubmed Import

Date Deposited:

21 Nov 2022 11:56

Last Modified:

20 Dec 2022 14:40

Publisher DOI:


Related URLs:

PubMed ID:


Uncontrolled Keywords:

Erenumab Healthcare impact Migraine Quality of life Real-world evidence Switzerland




Actions (login required)

Edit item Edit item
Provide Feedback